Considering that AMLs with KMT2Ar, NUP98r and NPM1 are dependent on KMT2A/Menin66–68 and that several Menin inhibitors targeting KMT2Ar and NPM1 AML are in clinical trials69,70, our data suggest that other subtypes marked by HOX expression may also be candidates for Menin inhibitors. This evidence concerns the gene MEN1 and acute myeloid leukemia.